Premium
Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version)
Author(s) -
Kudo Masatoshi,
Ikeda Masafumi,
Ueshima Kazuomi,
Sakamoto Michiie,
Shiina Shuichiro,
Tateishi Ryosuke,
Hasegawa Kiyoshi,
Furuse Junji,
Miyayama Shiro,
Murakami Takamichi,
Yamashita Tatsuya,
Kokudo Norihiro
Publication year - 2019
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.13394
Subject(s) - medicine , response evaluation criteria in solid tumors , hepatocellular carcinoma , liver cancer , clinical trial , clinical practice , intrahepatic cholangiocarcinoma , radiofrequency ablation , cancer , oncology , complete response , chemotherapy , ablation , family medicine , phases of clinical research
Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation and transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2019 by the Liver Cancer Study Group of Japan based on the 2015 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2019 are as follows: (i) CEA and CA19‐9 have been newly added as tumor markers that should be recorded for use as criteria in the response evaluation for intrahepatic cholangiocarcinoma; (ii) the criteria now state that the details of molecular targeted therapy should be specified; and (iii) specific methods for overall evaluation are now described. Also, as an assessment of overall TE4 requires that TE4 is achieved in all nodules (even non‐target lesions), the same calculation methods described above are used. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally.